OCTA in Disease Management

OCTA in Disease Management

OCTA transforms the optometrist's role from disease detector to disease monitor. Structural OCT tells you what has happened to retinal architecture. OCTA tells you what is happening in the vasculature — right now, at this visit. That distinction matters most in chronic, progressing conditions where management decisions depend on detecting subtle changes before irreversible damage occurs.

This module covers the four conditions where OCTA has the strongest evidence base and the clearest clinical workflow: diabetic retinopathy, age-related macular degeneration, retinal vein occlusion, and glaucoma.

Diabetic Retinopathy on OCTA

Diabetic retinopathy on OCTA reveals vascular pathology that predates clinical fundus findings by years. Non-perfusion area, FAZ enlargement, and capillary dropout are detectable on OCTA before microaneurysms, dot hemorrhages, or exudates become visible on dilated exam or color fundus photography.

Finding	OCTA Appearance	Clinical Significance
FAZ enlargement	Increased FAZ area; irregular FAZ border; reduced circularity index	Early macular ischemia marker; correlates with visual function better than BCVA alone
Non-perfusion area (NPA)	Dark (avascular) patches in SCP and DCP; DCP more prominently affected	Ischemic risk stratification; supplements ETDRS grading
Microaneurysms	Focal bright dots in SCP — only perfused MAs detected; thrombosed MAs invisible	OCTA detects fewer MAs than FA; FA still preferred for total MA count
NVE / NVD	Abnormal bright vascular loops in inner retina slab extending above ILM	Pre-proliferative to proliferative conversion; detects neovascular fronds early
Capillary dropout	Loss of capillary signal in DCP — patchy, perivenular distribution	DCP more affected than SCP in early DR; predicts progression

For DME, OCTA adds the ischemic component that structural OCT misses entirely. A patient with DME and significant FAZ enlargement has a poorer visual prognosis than a patient with the same degree of edema and a normal FAZ — and the management implications differ. Anti-VEGF response is better in non-ischemic DME; laser and combination approaches should be considered earlier when the OCTA demonstrates significant macular ischemia.

AMD Monitoring with OCTA

AMD is the condition where OCTA delivers the most immediate, practice-changing impact for the optometrist. The two key applications are CNV activity monitoring in treated neovascular AMD and choriocapillaris perfusion mapping in geographic atrophy.

Neovascular AMD: After anti-VEGF treatment, CNV activity monitoring is the central question at every injection follow-up. B-scan fluid status answers "is there fluid?" — OCTA answers "is the lesion growing?" These are different questions with different implications for injection timing and interval management.

• Active CNV with fluid: Dense flower or sea fan network + fluid on B-scan — treatment indicated, do not extend interval
• Good treatment response: Decreased vessel density, resolved macula — treat-and-extend candidate; consider interval extension
• Quiescent CNV: Ghost vessels only, no fluid — extend injection interval; monitor for reactivation at next visit
• CNV reactivation: Increasing peripheral vessel density or new branching ± new fluid — do not extend; reassess treatment regimen

Geographic atrophy: OCTA detects choriocapillaris flow voids beneath intact RPE that precede visible GA on fundus exam and structural OCT. The choriocapillaris slab shows dark non-perfused areas at the GA margin — anticipating RPE loss by weeks to months. This application is advancing rapidly with the recent introduction of complement pathway therapies for GA, where monitoring lesion progression rate is critical.

Retinal Vein Occlusion: Perfusion Assessment

RVO management hinges on perfusion status. Clinical exam and BCVA are insensitive to subtle non-perfusion changes. OCTA provides objective, quantifiable perfusion data at every visit, making it one of the strongest non-AMD OCTA use cases in primary eye care.

Branch RVO: OCTA shows the perfusion deficit as a wedge-shaped zone of capillary non-perfusion in the affected quadrant. The DCP is more severely involved than the SCP, consistent with preferential venous drainage from the deep plexus. FAZ disruption may extend into the superior or inferior foveal capillary network depending on the occluded branch location.

Central RVO: Non-ischemic CRVO shows relatively preserved capillary density with mild FAZ enlargement. Ischemic CRVO shows massive multi-quadrant non-perfusion with near-complete DCP dropout in severe cases. OCTA-based NPA quantification supplements or replaces the need for FA in many monitoring visits.

Finding	Non-ischemic RVO	Ischemic RVO
Capillary density	Mildly reduced; arcade structure preserved	Severely reduced; arcade disruption throughout
FAZ	Mild enlargement; irregular border	Markedly enlarged; disrupted — may be unrecognizable
DCP involvement	Moderate; patchy dropout	Severe; often near-complete dropout
Collateral vessels	Forming — tortuous shunt vessels visible in SCP	May be insufficient to decompress the occluded segment
Visual prognosis	Better; correlates with FAZ preservation	Proportional to NPA extent; guarded

Collateral vessel formation — the tortuous, dilated shunt vessels developing around the occluded segment — is visible on OCTA as large-caliber abnormal vessels in the SCP. Distinguishing collateral vessels (positive prognostic finding) from neovascularization (requiring treatment consideration) is a critical skill that the OCTA-trained optometrist can develop through serial monitoring.

Glaucoma: Vessel Density Analysis

The glaucoma OCTA application differs from the other diseases in this module. For AMD, DR, and RVO, OCTA answers acute clinical questions. For glaucoma, OCTA's value is detecting structural-functional discordance and pre-perimetric progression — changes appearing on OCTA before they are detectable on visual field or RNFL analysis.

Peripapillary vessel density (ppVD): The vessel density ring around the optic nerve head correlates strongly with RNFL thickness but often demonstrates loss earlier in the glaucoma progression sequence. Sectoral ppVD defects — particularly inferior quadrant loss — correspond to arcuate visual field defects and may precede clinically detectable RNFL thinning.

Macular vessel density (mVD): Ganglion cell complex loss in the macular region produces detectable vessel density reduction in the SCP slab. The temporal and inferior parafoveal zones show early loss in many glaucoma phenotypes, detectable on OCTA before the ganglion cell analysis map shows statistically significant thickness change.

OCTA Parameter	Glaucoma Finding	Clinical Use
Peripapillary vessel density	Focal sectoral dropout — inferior greater than superior in early disease	Progression monitoring; complements RNFL thickness maps
Macular vessel density	Parafoveal SCP dropout — inferior temporal early	Detects pre-perimetric damage; ganglion cell layer correlation
ONH flow index	Reduced laminar microvasculature in rim tissue	Disc hemorrhage risk marker; optic nerve blood flow monitoring
Disc hemorrhage site	Local ppVD reduction at hemorrhage sector	Focal perfusion loss confirms hemorrhage as progression marker

Building Your OCTA-Based Management Protocol

Integrating OCTA into disease management requires a structured approach. The following framework is designed for optometrists who want a repeatable, defensible protocol for their most common OCTA use cases.

AMD Monitoring Protocol (Post-injection or Dry/Intermediate):

1. B-scan first — fluid status drives the immediate management decision
2. OCTA outer retina slab — CNV presence and vessel density trend
3. Compare vessel density to previous OCTA — document as increasing, stable, or decreasing
4. Decision: fluid present + increasing density = do not extend; fluid absent + decreasing density = extend interval

Diabetic Retinopathy Monitoring Protocol:

1. Determine ETDRS grade from clinical exam and structural OCT
2. OCTA SCP + DCP — quantify NPA and document FAZ metrics
3. At every visit: compare FAZ area to baseline; note new NPA zones
4. NPDR with FAZ enlargement → shorten recall interval; refer earlier for scatter if NPA expands significantly

RVO Follow-up Protocol:

1. B-scan for macular edema status — anti-VEGF trigger
2. OCTA for perfusion trend — is NPA stable, expanding, or resolving?
3. Document collateral vessel formation as a positive progression marker
4. Ischemic conversion (new NPA on OCTA) → immediate referral regardless of VA